Unintended Pregnancies Observed with Combined Use of the Levonorgestrel Contraceptive Implant and Efavirenz-based Antiretroviral Therapy: A Three-Arm Pharmacokinetic Evaluation over 48 Weeks

Clinical Infectious Diseases

Volumn 62, Issue 6, 2015, Pages 675-682

  Scarsi, Kimberly K ^a   Darin, Kristin M ^b,c   Nakalema, Shadia ^d   Back, David J ^e   Byakika Kibwika, Pauline ^d   Else, Laura J ^e   DIlly Penchala, Sujan ^e   Buzibye, Allan ^d   Cohn, Susan E ^c   Merry, Concepta ^b,d,f   Lamorde, Mohammed ^d  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES   (Uganda)

^e UNIVERSITY OF LIVERPOOL   (United Kingdom)

^f TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

Contraceptive implant; Efavirenz; Levonorgestrel; Nevirapine; Unintended pregnancy

Indexed keywords

EFAVIRENZ; LAMIVUDINE PLUS TENOFOVIR DISOPROXIL; LAMIVUDINE PLUS ZIDOVUDINE; LEVONORGESTREL; NEVIRAPINE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; BENZOXAZINE DERIVATIVE; CONTRACEPTIVE AGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ACNE; ADULT; ANTIVIRAL THERAPY; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST TENDERNESS; CONTRACEPTION; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG IMPLANT; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSERTION SITE DISCOMFORT; MAJOR CLINICAL STUDY; MEDICAL DEVICE COMPLICATION; MENSTRUAL IRREGULARITY; MOOD CHANGE; NAUSEA; OUTCOME ASSESSMENT; PARALLEL DESIGN; PLASMA CONCENTRATION-TIME CURVE; PREGNANCY OUTCOME; PRIORITY JOURNAL; SIDE EFFECT; UGANDAN; UNPLANNED PREGNANCY; ADOLESCENT; ADVERSE EFFECTS; BLOOD; CLINICAL TRIAL; DRUG EFFECTS; DRUG INTERACTION; ETHNOLOGY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PREGNANCY; TIME FACTOR; UGANDA;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BENZOXAZINES; CONTRACEPTIVE AGENTS, FEMALE; DRUG INTERACTIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LEVONORGESTREL; NEVIRAPINE; PREGNANCY; PREGNANCY, UNPLANNED; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; UGANDA;

EID: 84960077215     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/civ1001     Document Type: Article

References (33)

1. World Health Organization. Global summary of the AIDS epidemic, December 2014. Available at: http://www.who.int/hiv/data/epi-core-july2015.png?ua=1. Accessed 14 September 2015.
2. UNAIDS. How AIDS changed everything-MDG6: 15 years, 15 lessons of hope from the AIDS response. Available from: http://www.unaids.org/sites/default/files/media-asset/MDG6Report-en.pdf. Accessed 5 September 2015.
3. Reynolds HW, Janowitz B, Homan R, Johnson L. The value of contraception to prevent perinatal HIV transmission. Sex Transm Dis 2006; 33:350-6.
4. Reynolds HW, Janowitz B, Wilcher R, Cates W. Contraception to prevent HIVpositive births: current contribution and potential cost savings in PEPFAR countries. Sex Transm Infect 2008; 84(suppl 2):ii49-53.
5. World Health Organization. Medical eligibility criteria for contraceptive use, 5th edition 2015. Available at: http://apps.who.int/iris/bitstream/10665/181468/1/9789241549158-eng.pdf?ua=1 Accessed 15 September 2015.
6. World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization, 2013.
7. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization, 2015.
8. World Health Organization Policy Brief. Transition to new HIV treatment regimens-procurement and supply chain management issues. Geneva:World Health Organization. 2014.
9. Reproductive Health Supplies Coalition. Available at: http://rhsupplies.org. Accessed 12 September 15.
10. Jadelle [ package insert]. Auckland, New Zealand: Bayer New Zealand Limited Company. August 2010.
11. Carten ML, Kiser JJ, Kwara A, Mawhinney S, Cu-Uvin S. Pharmacokinetic interactions between the hormonal emergency contraception, levonorgestrel ( plan B), and efavirenz. Infect Dis Obstet Gynecol 2012; 2012:137192.
12. Stuart GS, Moses A, Corbett A, et al. Combined oral contraceptives and antiretroviral PK/PD in Malawian women: pharmacokinetics and pharmacodynamics of a combined oral contraceptive and a generic combined formulation antiretroviral in Malawi. J Acquir Immune Defic Syndr 2011; 58:e40-3.
13. Perry SH, Swamy P, Preidis GA,Mwanyumba A,Motsa N, Sarero HN. Implementing the Jadelle implant for women living with HIV in a resource-limited setting: concerns for drug interactions leaDing to unintended pregnancies. AIDS 2014; 28:791-3.
14. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. http://aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf. Accessed 14 September 2015.
15. World Health Organization. WHO statement on progestogen-only implants. Geneva: World Health Organization. September 2015. Available at: http://apps.who. int/iris/bitstream/10665/190063/1/WHO-RHR-15.20-eng.pdf?ua=1. Accessed 23 November 2015.
16. World Health Organization. Medical eligibility criteria for contraceptive use, 4th ed. Geneva: World Health Organization, 2009.
17. Uganda Ministry of Health. Addendum to the national antiretroviral treatment guidelines. Kampala: Uganda Ministry of Health, December 2013.
18. US Department of Health and Human Services, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Division of AIDS. Division of AIDS (DAIDS) Table for GraDing the Severity of Adult and Pediatric Adverse Events, Version 2.0. 2014. Available at: http://rsc.tech-res.com/Document/safetyandpharmacovigilance/DAIDS-AE-GRADING-TABLE-v2-NOV2014. pdf. Accessed 15 September 2015.
19. US Food and Drug Administration. Bioanalytical Method Validation. September 2013. Available at: http://www.fda.gov/downloads/Drugs/GuidanceCompliance RegulatoryInformation/Guidances/UCM368107.pdf. Accessed 5 September 2015.
20. Sivin I, Lahteenmaki P, Ranta S, et al. Levonorgestrel concentrations during use of levonorgestrel rod (LNG ROD) implants. Contraception 1997; 55:81-5.
21. La Porte CJL, Back DJ, Blaschke T, et al. Updated guidelines to perform therapeutic drug monitoring for antiretroviral agents. Rev Antiviral Ther 2006; 3:4-14.
22. Vieira CS, Bahamondes MV, de Souza RM, et al. Effect of antiretroviral therapy incluDing lopinavir/ritonavir or efavirenz on etonogestrel-releasing implant pharmacokinetics in HIV-positive women. J Acquir Immune Defic Syndr 2014; 66:378-85.
23. Patel RC, Onono M, Gandhi M, et al. Pregnancy rates in HIV-positive women using contraceptives and efavirenz-based or nevirapine-based antiretroviral therapy in Kenya: a retrospective cohort study. Lancet HIV 2015; 2:e474-82.
24. Leticee N, Viard JP, Yamgnane A, Karmochkine M, Benachi A. Contraceptive failure of etonogestrel implant in patients treated with antiretrovirals incluDing efavirenz. Contraception 2012; 85:425-7.
25. Matiluko AA, Soundararjan L, Hogston P. Early contraceptive failure of Implanon in an HIV-seropositive patient on triple antiretroviral therapy with zidovudine, lamivudine and efavirenz. J Fam Plann Reprod Health Care 2007; 33:277-8.
26. McCarty EJ, Keane H, Quinn K, Quah S. Implanon failure in an HIV-positive woman on antiretroviral therapy resulting in two ectopic pregnancies. Int J STD AIDS 2011; 22:413-4.
27. Lakhi N, Govind A. Implanon failure in patients on antiretroviral medication: the importance of disclosure. J Fam Plann Reprod Health Care 2010; 36:181-2.
28. Sivin I, Lahteenmaki P, Mishell DR Jr, et al. First week drug concentrations in women with levonorgestrel rod or Norplant capsule implants. Contraception 1997; 56:317-21.
29. Sivin I,Wan L, Ranta S, et al. Levonorgestrel concentrations during 7 years of continuous use of Jadelle contraceptive implants. Contraception 2001; 64:43-9.
30. World Health Organization. Hormonal contraceptive methods for women at high risk of HIV and living with HIV: 2014 guidance statement. Geneva: World Health Organization.
31. World Health Organization. Strategic considerations for strengthening and linkages between family planning and HIV/AIDS policies, programs, and services. Available at: http://www.who.int/reproductivehealth/publications/linkages/fp-hiv
32. Center for Drug Evaluation and Research (2003). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products-general considerations. US Food and Drug Administration. Available at: http://www.fda. gov/ohrms/dockets/ac/03/briefing/3995B1-07-GFI-BioAvail-BioEquiv.pdf. Accessed 21 December 2015.
33. Jacobstein R, Stanley H. Contraceptive implants: proviDing better choice to meet growing family planning demand. Global Health Sci Pract 2013; 1:11-7.